Intervention Ups Vegetable Intake in Breast Cancer Survivors: WHEL Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

SAN ANTONIO-A randomized dietary intervention study of 3,100 breast cancer survivors requires the study group to eat five vegetable servings and 16 oz of vegetable juice daily, a level of vegetable intake that has not previously been examined. By comparison, the women in the control group are following the National Cancer Institute (NCI) diet, which includes only three vegetable servings and no vegetable juice.

SAN ANTONIO—A randomized dietary intervention study of 3,100 breast cancer survivors requires the study group to eat five vegetable servings and 16 oz of vegetable juice daily, a level of vegetable intake that has not previously been examined. By comparison, the women in the control group are following the National Cancer Institute (NCI) diet, which includes only three vegetable servings and no vegetable juice.

The Women’s Healthy Eating and Living (WHEL) study is examining the effects of a diet rich in vegetables, fruit, and fiber on the health of breast cancer survivors, including cancer recurrences.

Despite the high level of vegetables required, participants in the study have been able to change their diet and maintain the change for more than 4 years, said Vicky E. Jones, MD, associate professor of medicine, University of California, San Diego, Cancer Center.

To confirm the dietary changes, investigators measured blood compounds, including beta-carotene, alpha-carotene, and lutein levels. "These blood levels substantiate that the participants are making major changes in their vegetable intake, something that has not been accomplished in any of the other dietary intervention studies to date," Dr. Jones said.

The study participants also completed food frequency questionnaires and 24-hour dietary recalls, Dr. Jones said at a poster session of the 23rd Annual San Antonio Breast Cancer Symposium.

"This population is very motivated," Dr. Jones told ONI. Even before enrollment in the study, many of the women had already added more vegetables and fruits to their diet to meet the NCI recommendations, she said. The NCI daily diet includes two fruit servings, three vegetable servings, 20 g of fiber, and less than 30% of energy from fat. The WHEL diet requires three fruit servings, five vegetable servings, 16 oz of vegetable juice, 30 g of fiber, and 20% of energy from fat.

To encourage and promote the dietary changes, trained nutrition counselors make regular phone calls to the study participants. The study also sponsors cooking classes so that the women can learn new ways to prepare food to meet their vegetable and fruit requirements.

Enrollment was opened in 1995 and completed Nov. 30, 2000, Dr. Jones said. Eligible women had stage I (tumor 1 cm or larger), stage II, or stage IIIA tumors; diagnosis within 4 years of randomization; and no current chemotherapy.

To date, there have been approximately 200 relapses and 58 deaths. It is too early to evaluate outcome, she said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.